Navigation Links
Drug Surveillance System Needs to Be Fixed

The current drug surveillance system needs to be fixed, argues an editorial in this weeks BMJ.

The call follows a recent analysis of the diabetes drug rosiglitazone (Avandia) which raised serious questions about the drugs safety.

Rosiglitazone was approved by the US Food and Drug Administration (FDA) in 1999 and by the European Medicines Agency (EMEA) in 2000. Its popularity has increased steadily, with more than one million prescriptions written in the one year period ending March 2006 in England alone.

But last month an analysis of 42 trials of rosiglitazone, published in the New England Journal of Medicine, found that the drug was associated with an increased risk of heart attack and death from cardiovascular causes.

These emerging safety concerns highlight the need for a better system of drug evaluation both before and after approval, says Dr Dhruv Kazi from the London School of Economics.

He argues that the current approach relies heavily on passive surveillance and is based on reports of unusual adverse events from consumers, practitioners, manufacturers, and national regulatory authorities. Alternatively, the regulatory authorities may require further (phase IV) trials after approval, but these are often not completed in a timely manner, he says.

This results in a fractured regulatory process, where postmarketing surveillance falls short of the standards the agencies set for themselves.

This is exemplified by the case of rosiglitazone, which comes from a family of drugs with well documented side effects, he writes. However, postmarketing safety data seven years after regulatory approval consist of a patchwork of heterogeneous manufacturer sponsored trials, many of which are unpublished.

The system needs to be fixed, he says. This will require systematic rethinking of the existing regulatory and funding processes, and expediting changes currently in the pipeline.

In the meantime, doctors will need to revisit the indication for the drug on a case by case basis, bearing in mind that several alternatives are cheaper, supported by robust evidence, and now perhaps safer, he concludes.


'"/>




Related medicine news :

1. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
2. Integrated Disease Surveillance Project Soon In The Country
3. Surveillance Program for Haemodialysis Reduces Infection
4. Estrogen Linked to Immune Surveillance in Breast Cancer
5. Low-risk Prostate Cancer Patients Prefer Surgery Over ‘active Surveillance
6. Time to Overhaul Australias Medicines Safety Surveillance System
7. Hong Kong, Guangdong Province To Increase Joint HIV/AIDS Surveillance
8. Early Warning System For Breast Cancer
9. Gene connected to Multi-System disorder discovered
10. Reviving the Immune System
11. Painkilling Patch As Effective As Intravenous Delivery Systems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Techniques.” The guide will ensure lab personnel have a basic understanding of the ... lab measurement protocols. Enhanced understanding will help them reduce waste and rework to ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... i2i ... one of the highest preliminary data vendors in the latest KLAS report, Population Health ... i2i has led the developing market for population health management (PHM). The latest ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... with BASF Human Nutrition into the Food & Beverage and ... been BASF’s channel partner throughout Canada and USA geographies east of the Rocky ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , powered ... and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This ... to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, ...
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology: